BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 27147897)

  • 41. Lin28B facilitates the progression and metastasis of pancreatic ductal adenocarcinoma.
    Wang Y; Li J; Guo S; Ouyang Y; Yin L; Liu S; Zhao Z; Yang J; Huang W; Qin H; Zhao X; Ni B; Wang H
    Oncotarget; 2017 Sep; 8(36):60414-60428. PubMed ID: 28947981
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Skp2-mediated Zeb1 expression facilitates cancer migration by a ubiquitination-independent pathway.
    Wang HC; Luo CW; Chen TY; Chen YZ; Fang SY; Lai CY; Hung WC; Wu CC; Chen LT; Liu YC; Pan MR
    Life Sci; 2022 Dec; 311(Pt A):121135. PubMed ID: 36349605
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of epithelial-mesenchymal transition and autophagy in pancreatic ductal adenocarcinoma invasion.
    Yang J; Liu Y; Liu S
    Cell Death Dis; 2023 Aug; 14(8):506. PubMed ID: 37550301
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dysbindin promotes pancreatic ductal adenocarcinoma metastasis by activating NF-κB/MDM2 via miR-342-3p.
    Zhu D; Zheng S; Fang C; Guo X; Han D; Tang M; Fu H; Jiang M; Xie N; Nie Y; Yao X; Chen Y
    Cancer Lett; 2020 May; 477():107-121. PubMed ID: 32120026
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions.
    Hernandez YG; Lucas AL
    World J Gastrointest Oncol; 2016 Jan; 8(1):18-29. PubMed ID: 26798434
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PSC-derived Galectin-1 inducing epithelial-mesenchymal transition of pancreatic ductal adenocarcinoma cells by activating the NF-κB pathway.
    Tang D; Zhang J; Yuan Z; Zhang H; Chong Y; Huang Y; Wang J; Xiong Q; Wang S; Wu Q; Tian Y; Lu Y; Ge X; Shen W; Wang D
    Oncotarget; 2017 Oct; 8(49):86488-86502. PubMed ID: 29156810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum Exosomal miRNA-1226 as Potential Biomarker of Pancreatic Ductal Adenocarcinoma.
    Wang C; Wang J; Cui W; Liu Y; Zhou H; Wang Y; Chen X; Chen X; Wang Z
    Onco Targets Ther; 2021; 14():1441-1451. PubMed ID: 33664577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer.
    Qu D; Weygant N; Yao J; Chandrakesan P; Berry WL; May R; Pitts K; Husain S; Lightfoot S; Li M; Wang TC; An G; Clendenin C; Stanger BZ; Houchen CW
    J Oncol; 2019; 2019():6402925. PubMed ID: 31467540
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma.
    Alvarez MA; Freitas JP; Mazher Hussain S; Glazer ES
    J Gastrointest Cancer; 2019 Jun; 50(2):207-213. PubMed ID: 30891677
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism.
    Zhu H; Xiao Y; Guo H; Guo Y; Huang Y; Shan Y; Bai Y; Lin X; Lu H
    Aging (Albany NY); 2021 Dec; 13(23):25089-25105. PubMed ID: 34863080
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor initiating cells in pancreatic cancer: A critical view.
    Kong B; Michalski CW; Kleeff J
    World J Stem Cells; 2009 Dec; 1(1):8-10. PubMed ID: 21607102
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Silencing of LAMC2 Reverses Epithelial Mesenchymal Transition and Inhibits Progression in Pancreatic Ductal Adenocarcinoma via Inactivation of the NF-κB Signaling Pathway.
    Huang L; Han Y; Zhou Q; Sun Z; Yan J
    Crit Rev Eukaryot Gene Expr; 2023; 33(4):13-23. PubMed ID: 37183943
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia-mesenchymal transition during pancreatic carcinogenesis.
    Niu N; Lu P; Yang Y; He R; Zhang L; Shi J; Wu J; Yang M; Zhang ZG; Wang LW; Gao WQ; Habtezion A; Xiao GG; Sun Y; Li L; Xue J
    Gut; 2020 Apr; 69(4):715-726. PubMed ID: 31300513
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis.
    Lemberger M; Loewenstein S; Lubezky N; Nizri E; Pasmanik-Chor M; Barazovsky E; Klausner JM; Lahat G
    Oncotarget; 2019 Apr; 10(27):2644-2656. PubMed ID: 31080555
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Comparative Endocrine Trans-Differentiation Approach to Pancreatic Ductal Adenocarcinoma Cells with Different EMT Phenotypes Identifies Quasi-Mesenchymal Tumor Cells as Those with Highest Plasticity.
    Schmidtlein PM; Volz C; Braun R; Thürling I; Lapshyna O; Wellner UF; Konukiewitz B; Lehnert H; Marquardt JU; Ungefroren H
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572891
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment.
    Nakkina SP; Gitto SB; Beardsley JM; Pandey V; Rohr MW; Parikh JG; Phanstiel O; Altomare DA
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947972
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Microbiome Tumor Axis: How the Microbiome Could Contribute to Clonal Heterogeneity and Disease Outcome in Pancreatic Cancer.
    Basu M; Philipp LM; Baines JF; Sebens S
    Front Oncol; 2021; 11():740606. PubMed ID: 34631577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.